全文获取类型
收费全文 | 12099篇 |
免费 | 752篇 |
国内免费 | 111篇 |
专业分类
耳鼻咽喉 | 162篇 |
儿科学 | 435篇 |
妇产科学 | 231篇 |
基础医学 | 1613篇 |
口腔科学 | 526篇 |
临床医学 | 1036篇 |
内科学 | 2834篇 |
皮肤病学 | 290篇 |
神经病学 | 798篇 |
特种医学 | 592篇 |
外科学 | 1629篇 |
综合类 | 110篇 |
现状与发展 | 1篇 |
一般理论 | 7篇 |
预防医学 | 1038篇 |
眼科学 | 186篇 |
药学 | 788篇 |
2篇 | |
中国医学 | 39篇 |
肿瘤学 | 645篇 |
出版年
2023年 | 64篇 |
2022年 | 153篇 |
2021年 | 286篇 |
2020年 | 204篇 |
2019年 | 332篇 |
2018年 | 376篇 |
2017年 | 249篇 |
2016年 | 271篇 |
2015年 | 320篇 |
2014年 | 393篇 |
2013年 | 465篇 |
2012年 | 650篇 |
2011年 | 699篇 |
2010年 | 461篇 |
2009年 | 405篇 |
2008年 | 558篇 |
2007年 | 655篇 |
2006年 | 606篇 |
2005年 | 524篇 |
2004年 | 467篇 |
2003年 | 388篇 |
2002年 | 400篇 |
2001年 | 293篇 |
2000年 | 356篇 |
1999年 | 276篇 |
1998年 | 206篇 |
1997年 | 207篇 |
1996年 | 170篇 |
1995年 | 159篇 |
1994年 | 174篇 |
1993年 | 141篇 |
1992年 | 149篇 |
1991年 | 167篇 |
1990年 | 152篇 |
1989年 | 167篇 |
1988年 | 134篇 |
1987年 | 125篇 |
1986年 | 130篇 |
1985年 | 137篇 |
1984年 | 80篇 |
1983年 | 56篇 |
1982年 | 51篇 |
1981年 | 56篇 |
1980年 | 57篇 |
1979年 | 60篇 |
1978年 | 68篇 |
1977年 | 50篇 |
1976年 | 51篇 |
1975年 | 64篇 |
1974年 | 57篇 |
排序方式: 共有10000条查询结果,搜索用时 15 毫秒
1.
Jose M. Morales Jose Angel Martinez-Flores Manuel Serrano Maria José Castro Francisco Javier Alfaro Florencio García Miguel Angel Martínez Amado Andrés Esther González Manuel Praga Estela Paz-Artal Antonio Serrano 《Journal of the American Society of Nephrology : JASN》2015,26(3):735-745
In the current immunosuppressive therapy era, vessel thrombosis is the most common cause of early graft loss after renal transplantation. The prevalence of IgA anti–β2-glycoprotein I antibodies (IgA-aB2GPI-ab) in patients on dialysis is elevated (>30%), and these antibodies correlate with mortality and cardiovascular morbidity. To evaluate the effect of IgA-aB2GPI-ab in patients with transplants, we followed all patients transplanted from 2000 to 2002 in the Hospital 12 de Octubre prospectively for 10 years. Presence of IgA-aB2GPI-ab in pretransplant serum was examined retrospectively. Of 269 patients, 89 patients were positive for IgA-aB2GPI-ab (33%; group 1), and the remaining patients were negative (67%; group 2). Graft loss at 6 months post-transplant was significantly higher in group 1 (10 of 89 versus 3 of 180 patients in group 2; P=0.002). The most frequent cause of graft loss was thrombosis of the vessels, which was observed only in group 1 (8 of 10 versus 0 of 3 patients in group 2; P=0.04). Multivariate analysis showed that the presence of IgA-aB2GPI-ab was an independent risk factor for early graft loss (P=0.04) and delayed graft function (P=0.04). There were no significant differences regarding patient survival between the two groups. Graft survival was similar in both groups after 6 months. In conclusion, patients with pretransplant IgA-aB2GPI-ab have a high risk of early graft loss caused by thrombosis and a high risk of delayed graft function. Therefore, pretransplant IgA-aB2GPI-ab may have a detrimental effect on early clinical outcomes after renal transplantation. 相似文献
2.
Dalton Luiz Schiessel Ricardo K. Yamazaki Marcelo Kryczyk Isabela Coelho de Castro Adriana A. Yamaguchi Danielle C. T. Pequito 《Nutrition and cancer》2016,68(8):1369-1380
Objective: Polyunsaturated fatty acids n-3 (PUFA n-3) have shown effects in reducing tumor growth, in particular eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA) abundantly present in fish oil (FO). When these fatty acids are provided in the diet, they alter the functions of the cells, particularly in tumor and immune cells. However, the effects of α-linolenic fatty acid (ALA), which is the precursor of EPA and DHA, are controversial. Thus, our objective was to test the effect of this parental fatty acid. Methods: Non-tumor-bearing and tumor-bearing Wistar rats (70 days) were supplemented with 1 g/kg body weight of FO or Oro Inca® (OI) oil (rich in ALA). Immune cells function, proliferation, cytokine production, and subpopulation profile were evaluated. Results: We have shown that innate immune cells enhanced phagocytosis capacity, and increased processing and elimination of antigens. Moreover, there was a decrease in production of pro-inflammatory cytokines (tumor necrosis factor-alpha (TNF-α) and interleukin 6 (IL-6)) by macrophages. Lymphocytes showed decreased proliferation capacity, increased cluster of differentiation 8 (CD8+) subpopulation, and increased TNF-α production. Conclusions: Oil rich in ALA caused similar immune modulation in cancer when compared with FO. 相似文献
3.
4.
5.
Fabrice Barlesi Edward B. Garon Dong-Wan Kim Enriqueta Felip Ji-Youn Han Joo-Hang Kim Myung-Ju Ahn Mary Jo Fidler Matthew A. Gubens Gilberto de Castro Veerle Surmont Qiao Li Anne C. Deitz Gregory M. Lubiniecki Roy S. Herbst 《Journal of thoracic oncology》2019,14(5):793-801
Introduction
In the phase II/III KEYNOTE-010 study (ClinicalTrials.gov, NCT01905657), pembrolizumab significantly prolonged overall survival over docetaxel in patients with previously treated, programmed death ligand 1–expressing (tumor proportion score ≥ 1%), advanced NSCLC. Health-related quality of life (HRQoL) results are reported here.Methods
Patients were randomized 1:1:1 to pembrolizumab 2 or 10 mg/kg every 3 weeks or docetaxel 75 mg/m2 every 3 weeks. HRQoL was assessed using European Organisation for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire (QLC) Core 30 (C30), EORTC QLQ–Lung Cancer 13 (LC13), and EuroQoL-5D. Key analyses included mean baseline-to-week-12 change in global health status (GHS)/quality of life (QoL) score, functioning and symptom domains, and time to deterioration in a QLQ-LC13 composite endpoint of cough, dyspnea, and chest pain.Results
Patient reported outcomes compliance was high across all three instruments. Pembrolizumab was associated with better QLQ-C30 GHS/QoL scores from baseline to 12 weeks than docetaxel, regardless of pembrolizumab dose or tumor proportion score status (not significant). Compared with docetaxel, fewer pembrolizumab-treated patients had “deteriorated” status and more had “improved” status in GHS/QoL. Nominally significant improvement was reported in many EORTC symptom domains with pembrolizumab, and nominally significant worsening was reported with docetaxel. Significant prolongation in true time to deterioration for the QLQ-LC13 composite endpoint emerged for pembrolizumab 10 mg/kg compared to docetaxel (nominal two-sided p = 0.03), but not for the 2-mg/kg dose.Conclusions
These findings suggest that HRQoL and symptoms are maintained or improved to a greater degree with pembrolizumab than with docetaxel in this NSCLC patient population. 相似文献6.
Toshiro Hara Rony Chanoch-Myers Nathan D. Mathewson Chad Myskiw Lyla Atta Lillian Bussema Stephen W. Eichhorn Alissa C. Greenwald Gabriela S. Kinker Christopher Rodman L. Nicolas Gonzalez Castro Hiroaki Wakimoto Orit Rozenblatt-Rosen Xiaowei Zhuang Jean Fan Tony Hunter Inder M. Verma Kai W. Wucherpfennig Itay Tirosh 《Cancer cell》2021,39(6):779-792.e11
- Download : Download high-res image (228KB)
- Download : Download full-size image
7.
8.
9.
John Lennon Silva Cunha Amanda Almeida Leite Thamiris de Castro Abrantes Lorena Passoni Vervloet Thayn Melo de Lima Morais Gerson de Oliveira Paiva Neto Tatiana Nayara Librio Kimura Snia Maria Soares Ferreira Ricardo Luiz Cavalcanti de Albuquerque‐Júnior Aline Corrêa Abraho Mario Jos Romaach Bruno Augusto Benevenuto de Andrade Oslei Paes de Almeida Ciro Dantas Soares 《Journal of cutaneous pathology》2021,48(1):24-33
10.
A. Guerrero Gómez N. González Jaramillo J.A. Castro Pérez 《Revista espa?ola de anestesiología y reanimación》2019,66(1):10-17